{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:49:01Z","timestamp":1790005741553,"version":"4.0.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.psychres.2018.12.053","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T20:21:36Z","timestamp":1544214096000},"page":"604-613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?"],"prefix":"10.1016","volume":"271","author":[{"given":"Haley V.","family":"Solomon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7507-8070","authenticated-orcid":false,"given":"Kevin W.","family":"Cates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8430-544X","authenticated-orcid":false,"given":"Kevin J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.psychres.2018.12.053_bib0001","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jagp.2017.05.012","article-title":"Pharmacogenetic decision support tools: a new paradigm for late-life depression?","volume":"26","author":"Abbott","year":"2018","journal-title":"Am. J. Geriatr. Psychiatr."},{"issue":"10","key":"10.1016\/j.psychres.2018.12.053_bib0002","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/chromsci\/bmt200","article-title":"Determination of paroxetine in blood and urine using micellar liquid chromatography with electrochemical detection","volume":"52","author":"Agrawal","year":"2014","journal-title":"J. Chromatogr. Sci."},{"issue":"5","key":"10.1016\/j.psychres.2018.12.053_bib0003","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/tpj.2014.85","article-title":"Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes","volume":"15","author":"Altar","year":"2015","journal-title":"Pharmacogenomics J."},{"issue":"5","key":"10.1016\/j.psychres.2018.12.053_bib0004","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/09540261.2013.825579","article-title":"Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy","volume":"25","author":"Altar","year":"2013","journal-title":"Int. Rev. Psychiatr."},{"issue":"3","key":"10.1016\/j.psychres.2018.12.053_bib0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s13167-017-0112-8","article-title":"Pharmacogenomics in the treatment of mood disorders: strategies and opportunities for personalized psychiatry","volume":"8","author":"Amare","year":"2017","journal-title":"Epma. J."},{"key":"10.1016\/j.psychres.2018.12.053_bib0006","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fphar.2017.00402","article-title":"Association between CYP2D6 genotypes and the risk of antidepressant discontinuation, dosage modification and the occurrence of maternal depression during pregnancy","volume":"8","author":"Berard","year":"2017","journal-title":"Front Pharmacol."},{"issue":"5","key":"10.1016\/j.psychres.2018.12.053_bib0007","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0042-105443","article-title":"Relation between CYP2D6 genotype, phenotype and therapeutic drug concentrations among nortriptyline and venlafaxine users in old age psychiatry","volume":"49","author":"Berm","year":"2016","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2018.12.053_bib0008","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/tpj.2013.12","article-title":"Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder","volume":"14","author":"Brandl","year":"2014","journal-title":"Pharmacogenomics J."},{"issue":"5","key":"10.1016\/j.psychres.2018.12.053_bib0009","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/sj.clpt.6100116","article-title":"Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects","volume":"81","author":"Brockmoller","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.psychres.2018.12.053_bib0010","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1345\/aph.1A254","article-title":"Discontinuing or switching selective serotonin-reuptake inhibitors","volume":"36","author":"Bull","year":"2002","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.psychres.2018.12.053_bib0011","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2217\/pgs.12.203","article-title":"Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels","volume":"14","author":"Conrado","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.psychres.2018.12.053_bib0012","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1176\/appi.psy.47.1.75","article-title":"Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19","volume":"47","author":"de Leon","year":"2006","journal-title":"Psychosomatics"},{"issue":"10","key":"10.1016\/j.psychres.2018.12.053_bib0013","first-page":"1107","article-title":"The GRACE checklist: a validated assessment tool for high quality observational studies of comparative effectiveness","volume":"22","author":"Dreyer","year":"2016","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"6","key":"10.1016\/j.psychres.2018.12.053_bib0014","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ajmg.b.32184","article-title":"Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research","volume":"162B","author":"Fabbri","year":"2013","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet"},{"issue":"8","key":"10.1016\/j.psychres.2018.12.053_bib0015","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.euroneuro.2018.05.009","article-title":"Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies","volume":"28","author":"Fabbri","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2018.12.053_bib0016","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pnpbp.2018.05.007","article-title":"Pharmacogenetic tests to guide drug treatment in depression: comparison of the available testing kits and clinical trials","volume":"86","author":"Fabbri","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatr."},{"issue":"6","key":"10.1016\/j.psychres.2018.12.053_bib0017","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/15563650.2015.1049355","article-title":"CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants","volume":"53","author":"Haufroid","year":"2015","journal-title":"Clin. Toxicol. (Phila)"},{"issue":"8","key":"10.1016\/j.psychres.2018.12.053_bib0018","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/FPC.0000000000000290","article-title":"Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder","volume":"27","author":"He","year":"2017","journal-title":"Pharmacogenet. Genom."},{"issue":"2","key":"10.1016\/j.psychres.2018.12.053_bib0019","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.psychres.2018.12.053_bib0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.psychres.2018.12.053_bib0021","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/0269881113512041","article-title":"Genetic differences in cytochrome P450 enzymes and antidepressant treatment response","volume":"28","author":"Hodgson","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"14","key":"10.1016\/j.psychres.2018.12.053_bib0022","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1007\/s00213-015-3898-x","article-title":"Exploring the role of drug-metabolising enzymes in antidepressant side effects","volume":"232","author":"Hodgson","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"10.1016\/j.psychres.2018.12.053_bib0023","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1176\/appi.ajp.2017.17050550","article-title":"Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients","volume":"175","author":"Jukic","year":"2018","journal-title":"Am. J. Psychiatr."},{"issue":"5","key":"10.1016\/j.psychres.2018.12.053_bib0024","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","article-title":"Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response","volume":"9","author":"Kirchheiner","year":"2004","journal-title":"Mol. Psychiatr."},{"issue":"12","key":"10.1016\/j.psychres.2018.12.053_bib0025","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1177\/0269881114543720","article-title":"CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation","volume":"28","author":"Kumar","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.psychres.2018.12.053_bib0026","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1124\/dmd.31.9.1142","article-title":"Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects","volume":"31","author":"Lantz","year":"2003","journal-title":"Drug. Metab. Dispos."},{"issue":"7","key":"10.1016\/j.psychres.2018.12.053_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.psychres.2018.12.053_bib0028","doi-asserted-by":"crossref","first-page":"69","DOI":"10.31887\/DCNS.2010.12.1\/dmrazek","article-title":"Psychiatric pharmacogenomic testing in clinical practice","volume":"12","author":"Mrazek","year":"2010","journal-title":"Dialogues Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.psychres.2018.12.053_bib0029","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3109\/09540261.2013.838944","article-title":"Towards the implementation ofCYP2D6andCYP2C19genotypes in clinical practice: Update and report from a pharmacogenetic service clinic","volume":"25","author":"M\u00fcller","year":"2013","journal-title":"Int. Rev. Psychiatr."},{"issue":"5","key":"10.1016\/j.psychres.2018.12.053_bib0030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/hup.2340","article-title":"Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression","volume":"28","author":"Ng","year":"2013","journal-title":"Hum. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.psychres.2018.12.053_bib0031","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1124\/dmd.116.071639","article-title":"The use of in vitro data and physiologically-based pharmacokinetic modeling to predict drug metabolite exposure: desipramine exposure in cytochrome P4502D6 extensive and poor metabolizers following administration of imipramine","volume":"44","author":"Nguyen","year":"2016","journal-title":"Drug. Metab. Dispos."},{"issue":"1","key":"10.1016\/j.psychres.2018.12.053_bib0032","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2165\/00003088-199528010-00004","article-title":"Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline","volume":"28","author":"Nordin","year":"1995","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.psychres.2018.12.053_bib0033","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1176\/appi.ajp.163.1.101","article-title":"Continuity of antidepressant treatment for adults with depression in the united states","volume":"163","author":"Olfson","year":"2006","journal-title":"Am. J. Psychiatr."},{"issue":"1","key":"10.1016\/j.psychres.2018.12.053_bib0034","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/mp.2012.91","article-title":"CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients","volume":"18","author":"Penas-Lledo","year":"2013","journal-title":"Mol. Psychiatr."},{"issue":"18","key":"10.1016\/j.psychres.2018.12.053_bib0035","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1001\/jama.286.18.2270","article-title":"Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review","volume":"286","author":"Phillips","year":"2001","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.psychres.2018.12.053_bib0036","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1517\/17425255.2011.597740","article-title":"Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism","volume":"7","author":"Porcelli","year":"2011","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.psychres.2018.12.053_bib0037","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/01.pra.0000367777.96012.83","article-title":"Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters","volume":"16","author":"Preskorn","year":"2010","journal-title":"J. Psychiatr. Pract."},{"issue":"2","key":"10.1016\/j.psychres.2018.12.053_bib0038","first-page":"225","article-title":"An observational study of Venlafaxine and CYP2D6 in clinical practice","volume":"60","author":"Rolla","year":"2014","journal-title":"Clin. Lab."},{"issue":"06","key":"10.1016\/j.psychres.2018.12.053_bib0039","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4088\/JCP.15r10583","article-title":"Does pharmacogenomic testing improve clinical outcomes for major depressive disorder?","volume":"78","author":"Rosenblat","year":"2017","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.psychres.2018.12.053_bib0040","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jad.2018.08.056","article-title":"The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis","volume":"241","author":"Rosenblat","year":"2018","journal-title":"J. Affect Disord."},{"issue":"6","key":"10.1016\/j.psychres.2018.12.053_bib0041","first-page":"572","article-title":"Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources","volume":"26","author":"Rotzinger","year":"1998","journal-title":"Drug. Metab. Dispos."},{"issue":"16","key":"10.1016\/j.psychres.2018.12.053_bib0042","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2217\/pgs-2017-0116","article-title":"Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety","volume":"18","author":"Saiz-Rodriguez","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.psychres.2018.12.053_bib0043","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bcpt.12938","article-title":"Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of sertraline in healthy volunteers","volume":"122","author":"Saiz-Rodriguez","year":"2018","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.psychres.2018.12.053_bib0044","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40291-013-0028-5","article-title":"Applications of CYP450 testing in the clinical setting","volume":"17","author":"Samer","year":"2013","journal-title":"Mol. Diagn. Ther."},{"issue":"6","key":"10.1016\/j.psychres.2018.12.053_bib0045","doi-asserted-by":"crossref","first-page":"e2473","DOI":"10.1097\/MD.0000000000002473","article-title":"Role of pharmacogenetics in improving the safety of psychiatric care by predicting the potential risks of mania in CYP2D6 poor metabolizers diagnosed with bipolar disorder","volume":"95","author":"Sanchez-Iglesias","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.psychres.2018.12.053_bib0046","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0893-133X(95)00112-Q","article-title":"Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo","volume":"14","author":"Sprouse","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.psychres.2018.12.053_bib0047","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/pgs-2017-0003","article-title":"Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?","volume":"18","author":"Taranu","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.psychres.2018.12.053_bib0048","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2174\/1389202918666170426164940","article-title":"Optimization of antidepressant use with pharmacogenetic strategies","volume":"18","author":"Torrellas","year":"2017","journal-title":"Curr. Genomics."},{"issue":"1","key":"10.1016\/j.psychres.2018.12.053_bib0049","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatr."},{"issue":"6","key":"10.1016\/j.psychres.2018.12.053_bib0050","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","article-title":"The STAR*D Project results: a comprehensive review of findings","volume":"9","author":"Warden","year":"2007","journal-title":"Curr. Psychiatr. Rep."},{"issue":"4","key":"10.1016\/j.psychres.2018.12.053_bib0051","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9904","key":"10.1016\/j.psychres.2018.12.053_bib0052","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010","volume":"382","author":"Whiteford","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.psychres.2018.12.053_bib0053","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","article-title":"Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation","volume":"392","author":"Zanger","year":"2008","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.psychres.2018.12.053_bib0054","first-page":"113","article-title":"Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder","volume":"11","author":"Zastrozhin","year":"2018","journal-title":"Pharmgenomics. Pers. Med."},{"issue":"11","key":"10.1016\/j.psychres.2018.12.053_bib0055","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.psychres.2018.12.053_bib0056","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.psychres.2018.12.053_bib0057","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamapsychiatry.2018.0834","article-title":"On the marketing and use of pharmacogenetic tests for psychiatric treatment","volume":"75","author":"Zubenko","year":"2018","journal-title":"JAMA Psychiatr."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178118318523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178118318523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:30:47Z","timestamp":1759037447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178118318523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":57,"alternative-id":["S0165178118318523"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2018.12.053","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2018.12.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}